February 28, 2018 07:35 AM EST

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data

Brittany Meiling

A biotechnology company near Philadelphia — armed with data from a Phase IIb trial — just got breakthrough status from the FDA for a drug that might …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data

Brittany Meiling

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Ionis’ treatment for a rare metabolic disorder

Di­al­ing down the tox­ic ef­fects of ra­di­a­tion on can­cer pa­tients, Galera gets break­through sta­tus on Phase IIb da­ta

Brittany Meiling

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Ionis’ treatment for a rare metabolic disorder